Академический Документы
Профессиональный Документы
Культура Документы
Zong-Mei Wu, Zhen-Jiang Yu, Zhen-Qiang Cui, Lu-Yuan Peng, Hao-Ran Li, Chun-Lei
Zhang, Hai-Qing Shen, Peng-Fei Yi, Ben-Dong Fu
PII: S0882-4010(17)30527-2
DOI: 10.1016/j.micpath.2017.07.006
Reference: YMPAT 2344
Please cite this article as: Wu Z-M, Yu Z-J, Cui Z-Q, Peng L-Y, Li H-R, Zhang C-L, Shen H-Q, Yi P-F,
Fu B-D, In vitro antiviral efficacy of caffeic acid against canine distemper virus, Microbial Pathogenesis
(2017), doi: 10.1016/j.micpath.2017.07.006.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
PT
RI
SC
IC50(µg/ml) SI
Compounds CC50(µg/ml)
U
-1 h 0h 1h 2h -1 h 0h 1h 2h
AN
Caffeic acid >200 — — 23.3±0.9 32.3±0.7 — — >8.6 >6.2
M
D
TE
C EP
AC
ACCEPTED MANUSCRIPT
1 In vitro antiviral efficacy of caffeic acid against canine
2 distemper virus
3
4 Zong-Mei Wu#, Zhen-Jiang Yu#, Zhen-Qiang Cui, Lu-Yuan Peng, Hao-Ran Li,
5 Chun-Lei Zhang, Hai-Qing Shen, Peng-Fei Yi*, Ben-Dong Fu
6
7 Department of Clinical Veterinary Medicine, College of Veterinary Medicine,
PT
8 Jilin University, No. 5333 Xi'an Road, Changchun, Jilin 130062, China
RI
10
SC
11
U
13 Department of Clinical Veterinary Medicine
AN
14 College of Veterinary Medicine
15 Jilin University
M
18 Tel: +86-431-87835379
TE
20
21
22
C
23
AC
24
25
26
27
28
29
30
1
ACCEPTED MANUSCRIPT
31 Abstract
33 distemper virus (CDV), and mortality can be as high as 100%. However, there is no
34 specific treatment for CD. In this study, the antiviral activity of the caffeic acid against
35 CDV was evaluated in vitro. The results showed that the IC50 of the caffeic acid
PT
36 against CDV at 1 and 2 h post infection (PI) is 23.3 and 32.3 µg/mL, respectively.
RI
37 Consistently, at 1 and 2 h PI, the caffeic acid exhibited a reduced (23.3-57.0% and
38 37.2-38.1%) viral inhibitory effect in vero cells. Furthermore, the caffeic acid plus
SC
39 Ribavirin (RBV) has greater antiviral activity against CDV than the caffeic acid or
40 RBV individually. In addition, the caffeic acid reduced the total viral RNA synthesis
41
U
by 59-86% at 24-72 h. Therefore, our data provided the experimental evidence that
AN
42 the caffeic acid effectively inhibited CDV infection in vero cells, which may
M
45
TE
46
EP
47
48
C
49
AC
50
51
52
53
54
55
2
ACCEPTED MANUSCRIPT
56 1. Introduction
59 canine population seems to have increased in the past decades worldwide and even
PT
61 became distemper [1-3]. CDV causes systemic infections similar to but distinct from
RI
62 human measles in carnivores such as canines, felids, ferrets, raccoons and seals, with
63 lethality rates, depending on the host, of up to 100% [4, 5]. However, there is no
SC
64 specific antiviral agent for the treatment of CD. The nucleoside analogue 1-(b-D-
66
U
commercially available molecule with a well-known antiviral activity towards several
AN
67 members of the Paramyxoviridae family [6-8]. Therefore, it is necessary to explore
M
68 new agent to treat CD. The antiviral activity of the caffeic acid (3, 4-
69 dihydroxycinnamic acid) has been reported for some viruses, including influenza A
D
70 virus [9]. Caffeic acid is an important phenolic compound commonly found in plants,
TE
71 foods, and propolis samples, particularly in the form of caffeic acid phenethyl ester
74 We hypothesized that the caffeic acid could have inhibitory effect on CDV.
AC
75 Therefore, in this study, our aim was to investigate the anti-CDV activity of the
79 Vero cells were used for the in vitro growth of CDV. Vero cells were cultured in
80 DMEM with 5% fetal bovine serum (FBS) (Gibco) and antibiotics (100 units /ml
3
ACCEPTED MANUSCRIPT
81 penicillin, and 100 µg/ml streptomycin (Gibco, USA) at 37 °C and 5 % CO2
82 atmosphere incubator.
83 The CDV-11 strain (purchased from Qilu Animal Health Products Co., Ltd.) was
84 propagated in vero cells using a 5% FBS medium and subsequently titrated. The viral
85 titer was expressed as the 50% infectious dose of the tissue culture (TCID50/mL).
PT
86 Assessment of CDV growth in vero cells was performed after incubation at 37 °C and
RI
87 5 % CO2 for 4d.
88 2.2. Reagents
SC
89 Caffeic acid (Purity>98%) and RBV (Purity>98%) were purchased from the
90 National Institute for the Control of Pharmaceutical and Biological Products (Beijing,
91
U
China), and their chemical structure were shown in Fig.1. They were dissolved in
AN
92 solution of dimethyl sulfoxide (DMSO) (Sigma, USA). The real-time RT-quantitative
PCR (qRT-PCR) and One Step PrimeScriptTM RT-PCR Kit were bought from Takara,
M
93
98 ( Amresco ) [13]. Vero cells were cultured into 96-well plate (106cells/well) of
C
99 incubation at 37℃ and 5% CO2. The cells were treated with the tested compounds
AC
100 diluted in DMEM at different concentrations (from 12.5 to 200 µg/ml), after 72h
101 washed twice with phosphate-buffered saline (PBS), and incubated with 20µl of MTT
102 (5mg/mL) for 4h, the salt formed was solubilized by adding DMSO (150 mL/well)
103 and shaking for 10min. The optical density (OD) was determined using an EnSpire
104 Multimode plate Reader (PE, USA) with a 490-nm excitation filter. The 50%
105 cytotoxic concentration (CC50) values were calculated at least three independent
4
ACCEPTED MANUSCRIPT
106 experiments.
108 The intracellular activity of caffeic acid against CDV was evaluated with a
109 cytopathic effect (CPE) reduction assay on confluent vero cells, using the method of
110 Reed and Muench. Vero cells seeded in 96-well plates were infected with CDV at
PT
111 37 ℃ in 5 % CO2, and the tested compounds (12.5 to 200 µg/ml) were added at
RI
112 different time post infection (-1, 0, 1 and 2 h), according to the study [14]. The 50%
113 inhibitory concentration (IC50) was defined as the compound concentration required to
SC
114 reduce viral CPE by 50% of the virus control. The IC50 values of caffeic acid and
115 RBV were calculated as the mean±SD at least three independent experiments. The
U
selectivity index (SI) was obtained by calculating the ratio of the CC50/IC50.
AN
116
118 To investigate the antiviral effect of caffeic acid at different stage, 96-well
119 microplates were seeded with vero cells monolayers (106 cells/well), incubated with
D
120 the tested compounds at different time post infection (-1, 0, 1 and 2 h), vero cells were
TE
121 infected with dilutions of CDV (10-105 TCID50/mL). The study was according to the
122 method described in a previous study [14]. At the presence of 100 % CPE in the virus
EP
123 controls (approximately 72h PI), the antiviral effect was calculated using the method
C
124 of Reed and Muench. The inhibition of CDV growth by the tested compounds was
AC
125 expressed as the TCID50 value at each time point. Assays were done in triplicate.
127 The reduction of viral growth in the presence of the tested compounds was evalu
128 ated using RNA quantification. Vero cells were seeded in 6-well plates were infected
129 with 500 TCID50 after an incubation time of 2h at 37 ℃ in 5% CO2, and vero cells we
130 re washed twice with PBS, then the tested compounds were added. After further incub
5
ACCEPTED MANUSCRIPT
131 ation of 24, 48 of 72h, the cells were harvested. One step Real Time PCR technique w
132 as used to quantify the copies of viral nucleic acid in the cells. The nucleotide sequenc
PT
136 st denaturation step at 42 ℃ for 5 min, 95 ℃ for 10s, followed by 40 cycles at 95 ℃ f
RI
137 or 5s, and 60 ℃ for 34s. Each sample and each dilution of the internal control were re
138 peated in duplicate during the same reaction, and the relative level of RNA expression
SC
139 was calculated as the mean of the two measurements.
U
140 2.7. Statistical analyses AN
141 All values are expressed as means ± SD. Differences between mean values of
142 normally distributed data were analyzed using one-way ANOVA (Dunnett’s t-test).
M
144 3. Results
D
145 3.1. The cytotoxicity of caffeic acid, RBV and caffeic acid plus RBV
TE
146 As shown in Fig. 2 A and B, the cytotoxicity was not observed in the cells
following the caffeic acid and RBV treatment for 72 h from 12.5 to 200 µg/ml
EP
147
148 compared with non-treated (control) cell. The CC50 values of the caffeic acid and
C
149 RBV were >200 µg/ml (Table 1). There is also no cytotoxicity of the caffeic acid (32
AC
150 µg/ml) plus RBV (8-16 µg/ml) and DMSO (4%) (Fig. 2C).
152 When post-infection for 1 and 2 h, the caffeic acid showed antiviral effect. When
153 pre-infection for -1 and 0 h, no antiviral activity against CDV was observed (see Table
154 1).
155 The caffeic acid reduced viral yield at times 1h (IC50 23.3 µg/mL and SI >8.6),
6
ACCEPTED MANUSCRIPT
156 and 2h (IC50 32.3 µg/mL and SI >6.2) PI, and the efficiency of antiviral activity of
157 RBV was demonstrated at times 1 h (IC50 12.2 µg/mL and SI >16.4), and 2h (IC50
159 3.3. The intracellular and extracellular antiviral activity of caffeic acid against
160 CDV
PT
161 To investigate the antiviral activity of caffeic acid against CDV, a time of
RI
162 addition assay was carried out by adding the caffeic acid at -1, 0, 1, and 2 h PI
163 (Fig.3). As shown in Fig. 3A, among the indicated concentrations, the caffeic acid
SC
164 did not have antiviral efficacy against CDV at -1 and 0 h PI. The antiviral effect of
165 the caffeic acid was demonstrated at 1 and 2 h PI. At 1 and 2 h PI, the caffeic acid
166
U
(32 µg/mL) exhibited a reduced viral titer (23.4± 1.6% and 37.2 ± 5.6%) in vero cells.
AN
167 The 2-fold dose of the caffeic acid exhibited a reduced viral titer (57.0 ± 5.5% and
M
168 38.1± 4.8%) at 1 and 2 h PI. As shown in Fig. 3B, RBV (8-16 µg/mL) did not have
169 antiviral efficacy against CDV at -1 h PI, while 32 µg/mL of RBV reduced 32.8 ±
D
170 2.4% of TCID50. At 0 h PI, RBV (16-32 µg/mL) exhibited a reduced viral titer (14.2
TE
171 ± 0.1% and 23.1 ± 5.5%). At 1 and 2 h PI, RBV (16-32 µg/mL) exhibited a reduced
172 viral titer (32.98-100%). The caffeic acid displayed antiviral effects against CDV in a
EP
173 dose-dependent manner at 1h PI, and no significant differences at 2 h PI. The RBV
C
175 examined the antiviral activity of the caffeic acid (32 µg/mL) plus RBV (8-16 µg/mL)
176 against CDV infection in vero cells. At -1 h, the viral titer reduced from 36.8 ± 0.8%
177 to 59.4 ± 3.1%; at 0 h, the viral titer reduced from 14.3 ± 0.2% to 25.9 ± 2.7%; at 1 h,
178 the viral titer reduced from 12 ± 4% to 31.7 ± 1.7%, and at 2 h, the viral titer reduced
179 from 53.6 ± 3.6% to 52.7 ± 4.4%. The caffeic acid plus RBV has greater antiviral
180 activity against CDV than the caffeic acid or RBV individually at -1 h and 0 h PI, no
7
ACCEPTED MANUSCRIPT
181 significant differences at 1 h and 2 h PI (Fig. 3C).
182 3.4. Caffeic acid inhibits viral RNA accumulation during CDV replication cycle
183 Vero cells were infected with CDV (500 TCID50) and incubated for 24, 48 and
184 72h. The reduction of the total viral RNA was expressed as RNA copies/µL (Fig.4).
185 The results showed that the caffeic acid (32-64µg/mL) reduced the total viral RNA
PT
186 by 60.05– 61.48 %, 65.4-59.35 %, 66.58-86.99 % at 24, 48 and 72 h, respectively.
RI
187 4. Discussion
188 In this study, we investigated the antiviral activity of the caffeic acid against
SC
189 CDV and its possible machanisms of action.
190 Since RBV has been reported to have effect of high inhibiting CDV [6], it was of
191
U
interest to assess whether the caffeic acid or the caffeic acid with RBV could also
AN
192 inhibit CDV. Our results showed that the caffeic acid in vitro had antiviral activity
M
193 against CDV. Evaluation of viral growth depended on the observation of CPE, we
194 found that the IC50 of the caffeic acid against CDV at 1 and 2 h is 23.3 and 32.4 µg/ml,
D
195 respectively compared with that of RBV as 12 and 16 µg/ml. The time of addition
TE
196 assay confirmed the antiviral activity of the caffeic acid is in a dose-dependent manner.
197 Consistent with this result, the caffeic acid aslo reduced viral RNA copies at different
EP
198 times PI. RBV is an example of such extrapolation and has demonstrated great
C
199 antiviral efficiency against MeV[15]. Consistent with these findings, we found that
AC
200 RBV exhibited the inhibitory effect on CDV at lower concentrations (16-32 µg/ml).
201 Interestingly, except that the caffeic acid plus RBV inhibited the viral intracellular
202 stage of replicative cycle, the caffeic acid plus RBV also inhibited the extracellular
203 phase of the replicative cycle of CDV compared with the caffeic acid or RBV
204 individually. At -1 h PI, the RBV (8µg/ml) had no inhibitory effect on CDV, but the
8
ACCEPTED MANUSCRIPT
206 The existence of different viral targets has been documented for RBV, such as
207 RNA polymerization and RNA capping enzymes for dengue virus, vaccinia virus and
208 hepatitis C virus [16-18]. We observed that the caffeic acid effectively inhibited the
210 peginterferon and ribavirin as a way for the treatment of hepatitis C [19]. The caffeic
PT
211 acid has been known to directly interact with Fyn kinase, one of the members of the
RI
212 non-receptor protein kinase family, resulting in an inhibition of the enzyme activity
213 [20]. It was also reported that the neuroprotective properties of the caffeic acid
SC
214 including anxiolytic effects, and the caffeic acid derivatives also possessed anti-
216
U
Maybe, these functions participated to reduce CDV replication, but how the
AN
217 caffeic acid inhibited CDV is needed to explore. The caffeic acid plus RBV possessed
M
218 higher antiviral effect than caffeic acid or RBV individually, at the -1 h and 0 h PI
219 stage, but the possible mechanisms will require further studies.
D
220 In conclusion, we demonstrated that the caffeic acid played antiviral activity
TE
221 against CDV infection in vero cells. Our findings indicated that the caffeic acid might
223 Acknowledgement
C
224 This work was supported by the Special Fund for Agro-scientific Research in the
AC
225 Public Interest (201403051) and. National Natural Science Foundation of China (No.
226 31372470).
229
9
ACCEPTED MANUSCRIPT
230 References
231 [1] Decaro N, Camero M, Greco G, Zizzo N, Tinelli A, Campolo M, et al. Canine
232 distemper and related diseases: report of a severe outbreak in a kennel. The new
233 microbiologica. 2004;27:177-81.
234 [2] Scagliarini A, Battilani M, Ciulli S, Prosperi S, Morganti L. Molecular analysis of
235 the NP gene of Italian CDV isolates. Veterinary research communications. 2003;27
236 Suppl 1:355-7.
237 [3] Ek-Kommonen C, Sihvonen L, Pekkanen K, Rikula U, Nuotio L. Outbreak off
PT
238 canine distemper in vaccinated dogs in Finland. The Veterinary record.
239 1997;141:380-3.
240 [4] Harder TC, Osterhaus AD. Canine distemper virus--a morbillivirus in search of
RI
241 new hosts? Trends in microbiology. 1997;5:120-4.
242 [5] von Messling V, Springfeld C, Devaux P, Cattaneo R. A ferret model of canine
243 distemper virus virulence and immunosuppression. Journal of virology.
2003;77:12579-91.
SC
244
245 [6] De Clercq E, Cools M, Balzarini J, Snoeck R, Andrei G, Hosoya M, et al. Antiviral
246 activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related
247 compounds. Antimicrobial agents and chemotherapy. 1991;35:679-84.
U
248 [7] Shigeta S, Mori S, Baba M, Ito M, Honzumi K, Nakamura K, et al. Antiviral
249 activities of ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide, and
6'-(R)-6'-C-methylneplanocin A against several ortho- and paramyxoviruses.
AN
250
251 Antimicrobial agents and chemotherapy. 1992;36:435-9.
252 [8] Leyssen P, Balzarini J, De Clercq E, Neyts J. The predominant mechanism by
253 which ribavirin exerts its antiviral activity in vitro against flaviviruses and
M
260 Stojko R, et al. Caffeic Acid phenethyl ester and ethanol extract of propolis induce the
261 complementary cytotoxic effect on triple-negative breast cancer cell lines. Molecules.
262 2015;20:9242-62.
263 [11] Touaibia M, Jean-Francois J, Doiron J. Caffeic Acid, a versatile pharmacophore:
EP
268 2005;68:198-202.
269 [13] Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival.
AC
270 Modifications to the tetrazolium dye procedure giving improved sensitivity and
271 reliability. Journal of immunological methods. 1986;89:271-7.
272 [14] Serkedjieva J, Ivancheva S. Antiherpes virus activity of extracts from the
273 medicinal plant Geranium sanguineum L. Journal of ethnopharmacology. 1999;64:59-
274 68.
275 [15] Gururangan S, Stevens RF, Morris DJ. Ribavirin response in measles
276 pneumonia. The Journal of infection. 1990;20:219-21.
277 [16] Goswami BB, Borek E, Sharma OK, Fujitaki J, Smith RA. The broad spectrum
278 antiviral agent ribavirin inhibits capping of mRNA. Biochemical and biophysical
279 research communications. 1979;89:830-6.
280 [17] Benarroch D, Egloff MP, Mulard L, Guerreiro C, Romette JL, Canard B. A
281 structural basis for the inhibition of the NS5 dengue virus mRNA 2'-O-
282 methyltransferase domain by ribavirin 5'-triphosphate. The Journal of biological
10
ACCEPTED MANUSCRIPT
283 chemistry. 2004;279:35638-43.
284 [18] Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin.
285 Reviews of infectious diseases. 1990;12:1139-46.
286 [19] Tanida I, Shirasago Y, Suzuki R, Abe R, Wakita T, Hanada K, et al. Inhibitory
287 Effects of Caffeic Acid, a Coffee-Related Organic Acid, on the Propagation of
288 Hepatitis C Virus. Japanese journal of infectious diseases. 2015;68:268-75.
289 [20] Kang NJ, Lee KW, Shin BJ, Jung SK, Hwang MK, Bode AM, et al. Caffeic acid, a
290 phenolic phytochemical in coffee, directly inhibits Fyn kinase activity and UVB-
291 induced COX-2 expression. Carcinogenesis. 2009;30:321-30.
292 [21] Hall S, Desbrow B, Anoopkumar-Dukie S, Davey AK, Arora D, McDermott C, et
PT
293 al. A review of the bioactivity of coffee, caffeine and key coffee constituents on
294 inflammatory responses linked to depression. Food research international.
295 2015;76:626-36.
RI
296
297
298
SC
299
300
301
302
U
303
304
AN
305
306
307
M
308
309
310
D
311
312
313
TE
314
315
316
EP
317
318
319
320
C
321
AC
322
323
324
325
326
327
328
329
330
331
332
333
11
ACCEPTED MANUSCRIPT
334 Figure Captions
335 Figure 1. Chemical structures of Caffeic acid (A) and RBV (B)
336 Figure 2. Cytoxicity of Caffeic acid, RBV, and Caffeic acid plus RBV on vero
337 cells. (A) Cells were treated with 12.5-200 µg/mL for 72h. The cytoxicity was
338 evaluated using MTT assay. The viability of non-treated cells was considered to be
PT
339 100%. (B) Cytoxicity of RBV. (C) Cytoxicity of Caffeic acid plus RBV and 4 %
RI
340 DMSO. Experiments were done in triplicate. The data were analyzed by one-way
SC
342 Figure 3. Inhibitory effects of caffeic acid and RBV at different stages. (A) The
343 virus titer was reduced, Caffeic acid as an inhibitor on CDV has been shown after the
344
U
addition of 32-64 µg/mL at different times PI. (B) After the addition of 8-32 µg/mL of
AN
345 RBV at different times PI. The virus titer was examined. (C) The inhibitory effect of
M
346 Caffeic acid plus RBV against CDV were examined at different times PI. Experiments
347 were done in triplicate, and all differences are statistically significant in relation to
D
348 control (**P<0.01). The data were analyzed by one-way ANOVA (Dunnett’s t-test).
TE
349 Figure 4. Antiviral effect of caffeic acid against CDV replication in vero cells by
350 real-time RT-PCR at three different times PI. Viral growth was measured in the
EP
351 presence of different concentrations of Caffeic acid after 24, 48, and 72 h PI. Viral
C
352 RNA was quantified by real time PCR and the total RNA is expressed in copies/µl.
AC
353 Experiments were done in triplicate, and all differences are statistically significant in
354 relation to control (**P<0.01). The data were analyzed by one-way ANOVA
356
357
358
12
ACCEPTED MANUSCRIPT
359 Table
360 Table 1 Cytotoxicity, anti-CDV activity and selectivity indices of the tested compounds.
IC50(µg/ml) SI
Compounds CC50(µg/ml)
-1 h 0h 1h 2h -1 h 0h 1h 2h
PT
361 a CC50 and IC50 values represent means ± SD.
RI
363 c Stages of CDV replicative cycle: pre-treatment (1 h), adsorption (0 h), penetration (1 h), and intracellular (2 h).
364 The values are expressed as the means ± SD of the CC50 and IC50 values after at least three independent
SC
365 experiments.
366
U
367
AN
368
M
D
TE
C EP
AC
13
ACCEPTED MANUSCRIPT
PT
RI
U SC
AN
M
D
TE
EP
C
Fig.1
AC
ACCEPTED MANUSCRIPT
PT
RI
U SC
AN
M
D
TE
EP
C
AC
Fig.2
ACCEPTED MANUSCRIPT
PT
RI
U SC
AN
M
D
TE
EP
C
AC
Fig.3
ACCEPTED MANUSCRIPT
PT
RI
U SC
AN
M
D
TE
EP
C
AC
Fig.4
ACCEPTED MANUSCRIPT
Highlights
PT
replication cycle.
RI
3. The caffeic acid plus RBV inhibited the viral intracellular and
U SC
AN
M
D
TE
C EP
AC